Patents by Inventor Thierry Abribat
Thierry Abribat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110105390Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: Theratechnologies Inc.Inventors: Bruno LUSSIER, Luc Vachon, Soraya Allas, Thierry Abribat
-
Patent number: 7893025Abstract: The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: GrantFiled: October 20, 2004Date of Patent: February 22, 2011Assignee: Theratechnolgies Inc.Inventors: Bruno Lussier, Luc Vachon, Soraya Allas, Thierry Abribat
-
Publication number: 20100087366Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 8, 2010Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20090253623Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: October 8, 2009Applicant: THERATECHNOLOGIES INC.Inventors: THIERRY ABRIBAT, ANDRE DE VILLERS, ALCIDE CHAPDELAINE, SORAYA ALLAS, DENIS GRAVEL
-
Publication number: 20090088383Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine
-
Publication number: 20090011985Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 23, 2007Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20080167222Abstract: The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: ApplicationFiled: October 20, 2004Publication date: July 10, 2008Applicant: THERATECHNOLOGIES INC.Inventors: Bruno Lussier, Luc Vachon, Soraya Allas, Thierry Abribat
-
Patent number: 7316997Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 20, 2004Date of Patent: January 8, 2008Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Patent number: 7067488Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.Type: GrantFiled: September 25, 2003Date of Patent: June 27, 2006Assignee: TheraTechnologies Inc.Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
-
Publication number: 20050197288Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 20, 2004Publication date: September 8, 2005Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20040127412Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:Type: ApplicationFiled: September 25, 2003Publication date: July 1, 2004Applicant: THERATECHNOILOGIES INC.Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
-
Publication number: 20040023882Abstract: Protease-resistant analogues of biologically active derivatives of human PTH are described. These analogs are intended for use in therapeutic preparations for the treatment of various medical conditions in which bone loss is encountered or is susceptible of being encountered. The analogs specified are hPTH(1-34) and hPTH(1-31). More particularly, protease-resistant analogs of PTH adapted for transdermal administration are described.Type: ApplicationFiled: May 16, 2003Publication date: February 5, 2004Inventors: Krishna G. Peri, Kim High, Annie Bergeron, Serge Moffett, Thierry Abribat
-
Publication number: 20030204063Abstract: The present invention is concerned with modified biological peptides providing increased potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent, either at the N-terminal of the peptide, the C-terminal of the peptide, on a free amino or carboxyl group along the peptide chain, or at a plurality of these sites. Those peptides exhibit clinical usefulness for example in treating states of insulin resistance associated with pathologies such as type II diabetes.Type: ApplicationFiled: March 3, 2003Publication date: October 30, 2003Inventors: Denis Gravel, Abdelkrim Habi, Thierry Abribat
-
Patent number: 6148822Abstract: The present invention relates to an article such as a sole or a shoe adapted to contact the sole of a foot, which incorporates at least one unoriented mineral which is capable of developing a color in the wavelength range between about 400 nm and 900 nm and stimulates the reflex zones located at the sole of the foot. The method of utilizing such article is also disclosed.Type: GrantFiled: December 3, 1998Date of Patent: November 21, 2000Assignee: Asana LaboratoriesInventors: Christophe Cron, Thierry Pautrot, Thierry Abribat
-
Patent number: 6024093Abstract: An article such as a sole or a shoe adapted to contact the sole of a foot, which incorporates at least one crystalline substance which is capable of developing a color in the wavelength range between about 400 nm and 900 nm and stimulates the reflex zones located at the sole of the foot. The method of utilizing such article is also disclosed.Type: GrantFiled: February 8, 1999Date of Patent: February 15, 2000Assignee: Asana Laboratories Inc.Inventors: Christophe Cron, Thierry Pautrot, Thierry Abribat
-
Patent number: 5939386Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: August 23, 1996Date of Patent: August 17, 1999Assignee: Theratechnologies Inc.Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
-
Patent number: 5861379Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: August 23, 1996Date of Patent: January 19, 1999Assignee: Theratechnologies Inc.Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
-
Patent number: 5834418Abstract: The present invention relates to a process for the preparation of porcine platelet-extract containing matured growth factors, which comprises the steps of: a) centrifuging whole porcine blood at about 1000 g to about 5000 g to isolate the platelets from the platelet-rich-plasma; b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate the platelets; c) washing the concentrated platelets of step b); d) lyophilizing the washed platelets of step c); whereby causing lysis of the platelets and producing the platelet extract in optimal amount.Type: GrantFiled: March 20, 1996Date of Patent: November 10, 1998Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea, Michele Boushira
-
Patent number: 5817627Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, pro-GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm.sup.2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.Type: GrantFiled: June 14, 1996Date of Patent: October 6, 1998Assignee: Theratechnologies Inc.Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea